 |
 |
Events and News |
|
President
Bush and Mrs. Bush invited JN for the
Malaria-Awareness-Day....Watch Clip >
Malaria
President
Clinton Global Initiative.......Watch Clip >
CGl 2006
ano a
Mano
Medical in Bolivia....... Watch Clip
> Mano
a Mano
Meningitis
Vaccine Trials in Niger and Burkina Faso.....Watch Clip >
2003-2006 -
West Africa
|
|
 |
|
"Because of partnerships between developed countries and nations in the developing world, there's now a great optimism that the advantages enjoyed by so many in the developed world can be enjoyed by people everywhere. ... Through partnerships between the United States and the developing world, we're addressing pandemic disease." Mrs. Laura Bush
September 20, 2006 |
Development and Production of Low-Cost Vaccines &
Diagnostics for Developing Countries
Objective: To eliminate preventable infectious diseases through the development and production of low-cost vaccines and rapid diagnostic test kits.
Strategies:
1. The manufacture of a meningococcal A, C, Y, W-135 vaccine.
2. The development and production of a meningococcal A,C,Y,W-135 conjugate vaccine.
3. The sale and distribution of rapid test kits for malaria, TB, and HIV.
4. The development and clinical testing of a stroke and epilepsy vaccine.
5. The development and clinical testing of a Hepatitis C vaccine.
6. The construction of a manufacturing and vial facility near JN's current headquarters.
7. Development of Supply chain in West Africa by construction of bottling plant in Abidjan and cold storage facilities in Abidjan, Ouagadougou, Niamey, Kampala, Senegal, Mali, Togo and Benin.
This project is designed to address the growing need for biological products in developing countries, especially Africa. There is an increasing demand for meningococcal vaccines in developed countries, and unfortunately this demand has created a shortage throughout Africa. This is where the private sector and NGO must assure a major role. JN, with the help of charitable organizations and its worldwide business partners, will be able to provide low cost effective vaccines to prevent infectious diseases.
Geographic Scope: Africa, South East Asia, South America
Oct. 2006-2007
Milestones and Key Actions:
AFRICA: Vaccine Division: Initial manufacture of 1-2 million doses of Meningococcal A, C, Y, W-135 polysaccharide vaccine completed at the end of 2007. Utilizing its newly completed facilities in Omaha, NE, JN hopes to complete the initial large-scale production of 2 million doses of its Meningococcal A, C, Y, W-135 polysaccharide vaccine. Clinical Research Trials: Clinical trials for Meningococcal A, C, Y, W-135 DT Conjugate vaccine Clinical trials going on in North Côte d'Ivoire and this meningococcal conjugate vaccine developed by JN for sale primarily in African children. Diagnostic Division: Supply of 2 million Malaria, Tuberculosis, and HIV 1/2 rapid diagnostic test kits to West Africa: February 2007. JN has had a long-standing relationship with contract manufacture facilities in the US, which enables us large-scale production capabilities for rapid diagnostic tests for Malaria, TB, and HIV. It is our goal to supply two million diagnostic tests for Malaria, TB, and HIV to West Africa in 2007.
WEST AFRICA: Meningitis survivors among disease's victims
 SOUTH AMERICA: JNI MedicalUSA, to screen 2.5 children under the age of 18 for the presence of Tuberculosis in Bolivia in an association of Mano a Mano Medical Services, Bolivia.
Miles stone achievement: JNI Medical Côte d'Ivoire, provides 1 million Malaria, HIV and TB tests for screening and prevention in Ivory Coat, Burkina Faso, Niger, Mali, Senegal, Benin, Togo, Chad, Cameroon, Sierra Leone,Gambia, Ghana, Guineaand Mauritania 2006-2007. JNI Medical Côte d'Ivoire, providing and stocked one million Meningococcal meningitis A+C vaccine (a third party vaccine) to Ivory Coat, Burkina Faso, Niger, Mali, Senegal, Benin, Togo, Chad, Cameroon, Sierra Leone,Gambia, Ghana, Guinea,and Mauritania 2006-2007
Partnership Opportunities:
JN Medical Corporation would be willing to consider partnership. Our company's outstanding needs are primarily financial, manufacture and research however we would welcome any partnership which would allow us to provide our products to global health organizations and foreign governments or affiliated organizations.
JN's Contribution to GBC for Prevention of Malaria in Zambia |
